EW - Edwards Lifesciences: TAVR Mitral And Tricuspid Segments Are Each Meaningful Compounders

• Edwards Lifesciences is a quality name that sits at the tip of the spear in cardiovascular value procedure offerings.
• The company has remained resilient in the face of the pandemic, and is well positioned to benefit from the rebound in procedure deferrals.
• ROIC has consistently beaten the hurdle over the last 10 years and remains a meaningful driver to valuations and multiples expansion.
• We feel shares therefore command a premium, and are fairly valued given the market's pricing of the growth vision.
• Here we cover all of the necessary parts in the investment debate for the benefit of investors in their own reasoning.

For further details see: